Feature
Nordic Pharma Announces European Launch of Lacrifill® Canalicular Gel
-
By
February 10, 2026
-
2 min
-
1
Lacrifill® launched in Europe in
-
2
It is a cross-linked hyaluronic acid gel.
-
3
Temporarily blocks tear drainage.
-
4
Provides relief for up to six months.
-
5
Affects 30% of the European population.
-
6
Important for cataract and LASIK surgery candidates.
-
7
Aims to optimize ocular surface health.
-
8
Supported by leading ophthalmology experts.
-
Nordic Pharma has launched Lacrifill®, a new therapy for dry eye, in Europe following its CE mark approval in 2025. This innovative cross-linked hyaluronic acid gel temporarily occludes the tear drainage system, enhancing tear film preservation and providing long-lasting relief for up to six months. Dry eye affects up to 30% of Europeans and poses challenges for patients undergoing surgeries like cataract or LASIK, potentially compromising outcomes. Experts believe Lacrifill® will improve ocular surface health before and after surgical procedures.
-
1
Lacrifill® launched in Europe in
-
2
It is a cross-linked hyaluronic acid gel.
-
3
Temporarily blocks tear drainage.
-
4
Provides relief for up to six months.
-
5
Affects 30% of the European population.
-
6
Important for cataract and LASIK surgery candidates.
-
7
Aims to optimize ocular surface health.
-
8
Supported by leading ophthalmology experts.
Listen Tab content
